Hypermethylation of E-cadherin in endometrial carcinoma

Jee Hyun Park1, Byung Ick Lee1, Eun Seop Song1, Sung Ook Whang1, Woo Young Lee1, Seong Jin Cho2

1Department of Obstetrics and Gynecology, College of Medicine, Inha University, Incheon,
2Department of Pathology, College of Medicine, Hallym University, Seoul, Korea

Objective: Hypermethylation of CpG island is a common mechanism for the inactivation of tumor suppressor genes. Hypermethylation of the E-cadherin promoter region has been rarely studied in endometrial carcinoma of Korean women. The purpose of this study is to investigate methylation status of E-cadherin promoter region in endometrial carcinomas and endometrial hyperplasias, and analyze the correlation with clinicopathologic variables in endometrial carcinomas.

Methods: We examined the methylation status of the E-cadherin promoter region using methylation specific polymerase chain reaction and immunohistochemical expression (IHC) of E-cadherin in 30 endometrioid endometrial carcinomas and 20 endometrial hyperplasias, and correlated these results with various clinicopathological factors of endometrial carcinomas.

Results: Decreased expression of E-cadherin was detected in 13 of 30 (43.3%) endometrial carcinomas and in 1 of 20 (5%) endometrial hyperplasias (p=0.009). Promoter hypermethylation was detected in 12 of 30 (40%) endometrial carcinomas and 2 of 20 (10%) endometrial hyperplasias (p=0.015). Methylation status did not have a significant influence on the tumor grade and lymph node metastasis. However, the hypermethylation rate was significantly higher in stage above Ic (p=0.025). Decreased expression of E-cadherin was associated with tumor grade, tumor stage, and lymph node metastasis in endometrial carcinomas (p=0.01, p=0.02, p=0.03). There was no correlation between DNA hypermethylation and decreased expression of E-cadherin in endometrial carcinomas (p>0.05).

Conclusion: These results indicate that hypermethylation of E-cadherin promoter region is a frequent event in endometrial carcinoma, which may play an important role in the progression of carcinogenesis. Also, the promoter methylation of E-cadherin in endometrial carcinoma was found to be significantly associated with higher stage above Ic.

Key Words: E-cadherin, Hypermethylation, IHC, Endometrial carcinoma

INTRODUCTION

Cadherins are a family of cell-cell adhesion molecules essential for tight connection between cells.1 E-cadherin is the major cadherin molecule expressed in epithelial cells. The cadherin-mediated cell adhesion system is known to act as an invasion suppressor system in cancer cells, since noninvasive cells can be transformed into invasive ones when treated with antibodies to block cadherin's function or with cadherin-specific antisense RNA,2,3 and transfection of human cancer cell lines with E-cadherin cDNA can reduce their invasiveness.4 Recently, immunohistochemical examination has revealed that decreased E-cadherin expression is associated with tumor dedifferentiation and progression in endometrial carcinoma5 and many other tumors.6-10

DNA methylation is one of the best-understood epigenetic changes in human cancers. DNA methylation may play roles in carcinogenesis by virtue of 3 mechanisms: 1) DNA cytosine methylation facilitates gene mutation, as 5-methyl-cytosine is deaminated to thymine; 2) aberrant DNA methylation may be associated with allelic loss; and 3) DNA methylation occurs frequently in CpG islands near regulatory regions of genes and affects the transcriptions of specific genes.11-13 CpG methylation has recently been shown to be an important mechanism in the transcriptional inactivation of E-cadherin, and CpG methylation around the promoter region of E-cadherin was found to be significantly correlated with reduced E-cadherin expression in various cancers.14 Though it has been thought that hypermethylation of the E-cadherin gene is associated with immunohistochemical expression, tumor progression, tumor grade, tumor invasion, and lymph node metastasis in various tumors, this has been rarely studied in endometrial carcinoma of Korean women. In the current study, we analyzed methylation status of the E-cadherin and E-cadherin expression in endometrial hyperplasias and endometrial carcinomas. Also, we correlated these results with various clinicopathological factors of endometrial carcinomas.
MATERIALS AND METHODS

1. Patients and tissue specimens

Samples of endometrial tissues were obtained from 50 women who had undergone hysterectomy or curettage at the Inha University Hospital, Incheon and the Hallym University Hospital, Seoul, Korea, between 1995 and 2002. Endometrial hyperplasia tissues (n=20) were taken from the endometrial curettage and diagnosed according to the system of the World Health Organization. As a result, fifteen cases were found to be simple hyperplasias and five cases were atypical endometrial hyperplasias. Endometrial carcinoma tissues (n=30) were taken from surgical resection. None of the patients had undergone preoperative chemotherapy.

Pathologic stage, grade, and histological subtype were determined for each surgical specimen according to 1988 International Federation of Gynecology and Obstetrics (FIGO) system. Slides from each case were re-reviewed by a gynecological pathologist to verify the diagnosis, stage, grade, and histological type. The tumor grade resulted in 9 cases of tumor grade G1 (well differentiated carcinoma), 7 cases of G2 (moderately differentiated carcinoma), 14 cases of G3 (poorly differentiated carcinoma). All of the endometrial carcinomas were endometrioid endometrial carcinomas. Surgical stage resulted in 6 cases Ia, 9 cases Ib, 9 cases Ic, 4 cases II, 2 cases III (Table 1). Clinical data of patients were obtained from medical records. Tumor tissues were frozen in liquid nitrogen, and stored at −80°C until use.

2. Immunohistochemistry (IHC)

Tissues were fixed overnight in 10% buffered formalin, dehydrated, and embedded in paraffin. Five micrometer serial sections of each sample were used. Sections were cut, floated onto albumin coated slides, dried at 56°C, deparaffinized in xylene, rehydrated, and washed with phosphate-buffered saline (PBS) for 15 minutes at room temperature. Specimens were treated in a microwave oven in 0.01 mol/L citrate buffer (pH 6.0) for 30 minutes at 100°C, slowly cooled to room temperature, and then washed with PBS for 5 minutes at room temperature. After quenching endogenous peroxidase with 3% hydrogen peroxide in PBS for 10 minutes at room temperature, the sections were incubated with a blocking solution (PBS containing 5% skimmed milk) for 60 minutes at room temperature. Then the slides were incubated overnight at 4°C with a 1:100 dilution of anti-E-cadherin antibody (Monoclonal mouse anti E-cadherin, Zymed, CA, USA). After several washes with PBS, they were incubated with a second antibody, a 1:200 dilution of peroxidase conjugated anti-mouse immunoglobulin (LSAB kit, DAKO, Denmark), for two hours. 3,3’-diaminobenzidine tetrahydrochloride was used as a chromogen, and Mayer’s hematoxylin counterstain was applied. For the negative control, the same dilution of non-immunized mouse immunoglobulin was used as the first antibody. Blocks of normal endometrium tissues were prepared as controls from the normal endometrium tissues of ten patients with endometrial carcinomas. In accordance with previous reports, E-cadherin expression was considered "positive" when more than 70% of tumor cells showed strong membranous staining and "negative" or "decreased" when less than 70% of tumor cells showed strong membranous staining or showed only slight membranous staining (Fig. 1).

3. Methylation-specific PCR (MSP)

DNAs were extracted from tumor and nontumoral tissues with a genomic DNA purification kit (Promega, Madison, WI, USA). Both methylation-specific PCR (MSP) and bisulfite-PCR take advantage of the fact that unmethylated cytosine is efficiently converted to uracil after 16 hours of Na-bisulfite treatment, whereas methylated cytosines remain unchanged. To examine the DNA methylation patterns, we treated genomic DNA with sodium bisulfite, as described by Herman et al.17 In brief, 2 ug of genomic DNA was denatured by treatment with NaOH and modified 3 M sodium bisulfite for 16 hours. DNA samples were purified with Wizard DNA purification resin (Promega, Madison, WI, USA), treated with NaOH, precipitated with ethanol and resuspended in 25 ug of water. MSP was used to examine the methylation status of E-cadherin. The primer sequences of E-cadherin for the methylated and unmethylated reactions are described in Table 2. These primers were designed for the E-cadherin promoter region and contained six sites (116 bp) of the CpG promoter at genomic position of −205 for methylated-specific primers and five sites (97 bp) at genomic position of −210 for unmethylated-specific primers, respectively.17 PCR was performed in 10ug reaction volumes. PCR products underwent electrophoresis on 2% agarose gel and were then vi-
Hypermethylation of E-cadherin in endometrial carcinoma

**Fig. 1.** E-cadherin expression by immunohistochemical stain; A shows strong membranous expression of E-cadherin, along the intercellular boundaries (grade I endometrial carcinoma). B shows remarkable loss of immunoreactivity (grade III endometrial carcinoma).

**Table 2.** Primer sequences used in E-cadherin gene hypermethylation

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward primer (5′-3′)</th>
<th>Reverse primer (5′-3′)</th>
<th>Anneling temperature (°C)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ecad-U*</td>
<td>5′-TAATTTTAGGTTAGGGTTATTGT-3′</td>
<td>5′-CAACAACCATCAACAAACAA-3′ †</td>
<td>53</td>
</tr>
<tr>
<td>Ecad-M†</td>
<td>5′-TTAGGTTAGGGTTATTCCGT</td>
<td>5′-TAACTAAAAATTACACCGAC-3′ †</td>
<td>57</td>
</tr>
</tbody>
</table>

*unmethylated-specific primers, †methylated-specific primers

**Fig. 2.** Methylation analysis of E-cadherin promoter gene. The first case showed unmethylated. Case 43 and case 44 showed hypermethylated. U: unmethylated lane, M: methylated lane.

<table>
<thead>
<tr>
<th>Case 42</th>
<th>Case 43</th>
<th>Case 44</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>M</td>
<td>U</td>
<td>M</td>
</tr>
</tbody>
</table>

**Table 3.** DNA hypermethylation and protein expression of E-cadherin

<table>
<thead>
<tr>
<th></th>
<th>Endometrial hyperplasia (n=20)</th>
<th>Endometrial carcinoma (n=30)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypermethylation</td>
<td>2 (10%)</td>
<td>12 (40.0%)</td>
<td>0.015</td>
</tr>
<tr>
<td>IHC*</td>
<td>1 (5%)</td>
<td>13 (43.3%)</td>
<td>0.009</td>
</tr>
</tbody>
</table>

*protein expression loss by immunohistochemical stain

**4. Statistical analysis**

Statistical analysis of differences was assessed with chi-square test and Fisher’s exact test using SPSS ver. 15.0. Two sided tests were used to determine significance and p values less than 0.05 were regarded as statistically significant.

## RESULTS

1. **E-cadherin expression**

Decreased expression of E-cadherin was significantly associated with endometrial carcinomas than endometrial hyperplasias (p=0.009). Decreased expression of E-cadherin was detected 13 of 30 endometrial carcinomas (43.3%), 1 of 20 endometrial hyperplasias (5%) (Table 3). Decreased expression of E-cadherin was significantly associated with tumor dedifferentiation, advanced tumor stage, and lymph node metastasis in endometrial carcinomas (p=0.01, p=0.02, p=0.03) (Table 4).

2. **Promoter methylation of E-cadherin gene**

Hypermethylation of E-cadherin was more frequent in endometrial carcinomas than endometrial hyperplasias (p=0.015). Hypermethylation of E-cadherin was detected 12 of 30 endometrial carcinomas (40%), 2 of 20 endometrial hyperplasias (10%) (Table 3). Methylation status of E-cadherin of endometrial carcinomas had no correlation with the tumor grade and lymph node metastasis.
and when there was lymph node metastasis. Our results are in agreement with several previous studies. These results suggest that decreased expression of E-cadherin may play a role in carcinogenesis and be a prognostic factor for aggressive disease.

Work over the past several years has demonstrated that the silencing of tumor suppressor genes associated with promoter methylation is a common feature in human cancers. It was discovered that some tumor suppressor genes, including RB, VHL, p15, and p16, were inactivated as a result of reduced expression due to CpG methylation. As observed with these tumor suppressor genes, the E-cadherin invasion suppressor gene in human cancers is silenced by an epigenetic mechanism, promoter hypermethylation. But hypermethylation in the promoter region of E-cadherin has been rarely studied in endometrial carcinoma of Korean women. So we studied the promoter-region CpG island methylation of E-cadherin gene in endometrial hyperplasias and endometrial carcinomas.

### Table 4. E-cadherin gene hypermethylation and protein expression according to the clinicopathological factors in endometrial carcinomas

<table>
<thead>
<tr>
<th>Tumor grade</th>
<th>Hypermethylation</th>
<th>IHC*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (n=9)</td>
<td>p=NS</td>
<td>p=0.010</td>
</tr>
<tr>
<td>2 (n=14)</td>
<td>4 (44.4%)</td>
<td>2 (22.2%)</td>
</tr>
<tr>
<td>3 (n=7)</td>
<td>3 (42.9%)</td>
<td>6 (85.7%)</td>
</tr>
<tr>
<td>Tumor stage</td>
<td>p=0.025</td>
<td>p=0.020</td>
</tr>
<tr>
<td>IA (n=6)</td>
<td>1 (16.7%)</td>
<td>1 (16.7%)</td>
</tr>
<tr>
<td>IB (n=9)</td>
<td>3 (33.3%)</td>
<td>3 (33.3%)</td>
</tr>
<tr>
<td>IC (n=9)</td>
<td>5 (55.6%)</td>
<td>6 (44.4%)</td>
</tr>
<tr>
<td>II-III (n=6)</td>
<td>3 (50.0%)</td>
<td>3 (50.0%)</td>
</tr>
<tr>
<td>LN metastasis</td>
<td>p=NS</td>
<td>p=0.033</td>
</tr>
<tr>
<td>(+) (n=9)</td>
<td>3 (33.3%)</td>
<td>6 (66.7%)</td>
</tr>
<tr>
<td>(−) (n=21)</td>
<td>9 (42.9%)</td>
<td>7 (33.3%)</td>
</tr>
</tbody>
</table>

*protein expression loss by immunohistochemical stain
NS: not significant, LN: lymph node node

metastasis. However hypermethylation of E-cadherin was found in higher frequency in above stage Ic endometrial carcinomas (p=0.025) (Table 4).

#### 3. The correlation between hypermethylation and immunohistochemical findings of E-cadherin

There was no correlation between DNA methylation and immunohistochemical findings of E-cadherin in endometrial carcinomas. Seven of 17 samples (41.2%) with positive expression of E-cadherin showed methylation, whereas 5 of 13 samples (38.5%) with decreased expression of E-cadherin showed methylation (p > 0.05).

## DISCUSSION

Reduced cell-cell adhesiveness allows cancer cells to disobey the social order, resulting in destruction of the histologic structure, the morphologic hallmark of malignant tumors. Several reports have indicated that E-cadherin, an epithelial-specific cadherin, is a key molecule for the maintenance of epithelial integrity and of polarized states in association with alpha-, beta-, and gamma-catenin, and that the reduction of E-cadherin-mediated cell-cell adhesion favors the dispersion of cancer cells. Consistent with this concept, immunohistochemical studies have revealed that decreased E-cadherin expression is associated with tumor dedifferentiation and progression in endometrial carcinoma 5 and other tumors. In the current study, decreased expression of E-cadherin was of a higher incidence in endometrial carcinoma than endometrial hyperplasia. Decreased expression of E-cadherin in endometrial carcinoma was associated with tumor dedifferentiation (G1 < G2 < G3). The expression of E-cadherin also showed a tendency to decrease in advanced surgical stages and when there was lymph node metastasis. Our results are in agreement with several previous studies. These results suggest that decreased expression of E-cadherin may play a role in carcinogenesis and be a prognostic factor for aggressive disease.
tion, we noted positive E-cadherin expression in 26.7% of endometrial carcinomas. This suggests that mechanisms other than methylation are likely to be involved in impaired E-cadherin expression. Dysfunction of catenins or the effect of signals from other cell junctions might include the instability of E-cadherin expression. Saito et al.\textsuperscript{23} reported that hypermethylation in the promoter region of the E-cadherin gene correlated with tumor progression, tumor dedifferentiation, and the depth of myometrial invasion. Therefore, they suggested that methylation of the E-cadherin gene occurred in association with the acquisition of invasive capacity. But in the current study, methylation status in endometrial carcinomas had no correlation with the tumor grade and lymph node metastasis. However, DNA hypermethylation was found in higher frequency in above stage Ic endometrial carcinoma. Further study for confirmation of invasive capacity of E-cadherin in endometrial carcinoma is required.

These results indicate that hypermethylation of E-cadherin promoter region is a frequent event in endometrial carcinoma, which may play an important role in the progression of carcinogenesis. Also, the promoter methylation of E-cadherin in endometrial carcinomas was found to be significantly associated with higher stage above Ic endometrial carcinomas.

REFERENCES